AMRN’s meeting with the FDA regarding the Orange Book signifies nothing in particular, IMO. It’s a newbie mistake to assume that such a meeting implies that the drug in question will be approved on or before the PDUFA date.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”